How long is the usual medication cycle for Vepotolizumab/Urova?

Polatuzumab/Polatuzumab is a new antibody-drug conjugate (ADC), mainly used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL; non-Hodgkin lymphoma). It combines a monoclonal antibody targeting CD79b with a cytotoxic microtubule inhibitor called MMAE (monomethyl auristatin E) through a stable linker to achieve delivery and directly destroy tumor cells. Its unique mechanism of action makes it one of the important breakthroughs in the field of lymphoma treatment in recent years.

In terms of medication cycle, velpotuzumab is usually used in combination with bendamustine (Bendamustine) and rituximab (Rituximab) to form a common "Pola-BR" regimen. The standard recommended dose is intravenous infusion once every 21 days (i.e. 3 weeks) at a dose of 1.8 mg/kg. After each cycle, it is decided whether to continue the next round of treatment based on disease response and body tolerance. Normally, it is recommended to complete 6 cycles of treatment to achieve optimal results. If the patient responds well to the drug and tolerates it well, the doctor may consider extending the course of treatment or consolidating the treatment.

The length of the medication cycle is closely related to the patient's disease severity, tumor burden, previous treatment history and physical functional status. For some relapsed or refractory patients, velpotuzumab can significantly shrink tumor lesions and extend progression-free survival in combination therapy, but blood images, liver function and nervous system conditions need to be monitored regularly to ensure safety. If serious adverse reactions occur during treatment, such as peripheral neuropathy or infectious complications, doctors may suspend or adjust the dosing interval.

In general, the standard treatment course of vepotuzumab is6 three-week cycles, totaling about 18 weeks, which is a mid-course therapy. Following the physician's guidance and adjusting the treatment course individually is the key to ensuring efficacy and safety.

Reference materials:https://www.drugs.com/polivy.html